Multiple Sclerosis: Update Bulletin #1 [February 2018]
This edition presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) market. Topics covered include: Roche’s announcement that Ocrevus (ocrelizumab) has been approved by the European Commission as a treatment for RRMS and PPMS; Mylan announcing the UK launch of Brabio (glatiramer acetate injection; 40 mg/ml), a generic version of Copaxone; as well as Merck KGaA’s potential FDA resubmission for Mavenclad (cladribine tablets) as a therapy for relapsing forms of MS.
B
usiness Questions:
B
usiness Questions:
- How is Ocrevus expected to be prescribed once launched?
- Which agents are anticipated to lose market share as a result of Ocrevus’ launch?
- How do KOLs view Brabio and how successful is it likely to be?
- How do KOLs view Mavenclad, and how successful has the European launch been?
- How is Mavenclad currently prescribed?
More Publications
Multiple Sclerosis: Update Bulletin [March 2016]
US$ 995.00
March 2016
-
Multiple Sclerosis [2016]: Bulletin #2
US$ 1,045.00
June 2017
-
Multiple Sclerosis [2016]: Bulletin #3
US$ 1,045.00
July 2017
-
Multiple Myeloma: Update Bulletin #3 [March 2018]
US$ 1,095.00
February 2018
-
Multiple Myeloma: Update Bulletin #2
US$ 1,095.00
November 2017
-
